嘌呤能2X7受体(purinergic 2X7 receptor, P2X7R)是一种离子通道型受体,可引起核苷酸结合寡聚化结构域样受体3(nucleotide-binding oligomerization domain-like receptor protein 3, NLRP3)的激活,进而影响炎症细胞因子如IL-1β、IL-18等的释放从而参与多种炎症性疾病。近年来,P2X7R/NLRP3信号通路已成为炎症性疾病研究较多的通路之一,已有部分P2X7R和NLRP3炎性小体的拮抗剂进入早期的临床治疗。本文就P2X7R和NLRP3炎性小体的相关进展进行综述,为进一步验证P2X7R/NLRP3的激活导致IL-1β等炎症细胞因子在肿瘤和炎症性疾病中释放增加提供参考,为研究P2X7R/NLRP3作为肿瘤和炎症性疾病的重要病理机制和潜在的治疗靶点提供新的思路。
Purinergic 2X7 receptor (P2X7R) is an ionotropic receptor that is involved in various inflammatory diseases through affecting the release of inflammatory cytokines such as IL-1β and IL-18 after inducing the activation of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3). In recent years, the P2X7R/NLRP3 signaling pathway has become one of the more studied pathways in inflammatory diseases, and some inhibitors of P2X7R and NLRP3 have already been used in early clinical treatment. In this paper, the progress in P2X7R and NLRP3 was summarized, aiming to provide reference for further investigation on the roles of P2X7R/NLRP3 in the pathogenesis of tumors and inflammatory diseases and the potential of P2X7R/NLRP3 as therapeutic targets.
唐园园,贺樟平,吴移谋. P2X7受体及NLRP3炎性小体在炎症性疾病中的研究进展[J]. 中华微生物学和免疫学杂志,2023,43(04):316-321.
DOI:10.3760/cma.j.cn112309-20221017-00340版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。